Arrowhead Pharmaceuticals, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Arrowhead Pharmaceuticals, Inc. now
Current reporting with the operating signal separated from the noise.
TradingView
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $105.4, Implies 23% Upside
Investors are testing whether Arrowhead Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest ARWR filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2026-02-05 · Period 2025-12-31SEC ↗10-KAnnual financial reportFiled 2025-11-25 · Period 2025-09-30SEC ↗8-KMaterial company eventFiled 2026-06-16 · Period 2026-06-12SEC ↗8-KMaterial company eventFiled 2026-05-07 · Period 2026-05-07SEC ↗8-KMaterial company eventFiled 2026-03-20 · Period 2026-03-19SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-01-27 · Period 2026-01-26SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-07-31SEC ↗
Arrowhead Pharmaceuticals, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →